Comparative Pharmacology
Head-to-head clinical analysis: DEPOCYT versus TAZVERIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPOCYT versus TAZVERIK.
DEPOCYT vs TAZVERIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
None Documented
None Documented
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Category C
Category C
Antineoplastic
Antineoplastic, EZH2 Inhibitor